REG - PureTech Health PLC - Transaction in Own Shares

Puretech HealthAnnouncement

11/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231011:nRSK6983Pa&default-theme=true

RNS Number : 6983P  PureTech Health PLC  11 October 2023

11 October 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the
following number of its ordinary shares of one pence each through Jefferies
International Limited ("Jefferies"), as part of its Share Buyback Programme,
details of which were announced on 9 May 2022.

 

 Date of purchase:                              10 October 2023

 Number of ordinary shares purchased:           13,692

 Highest price paid per share:                  185.80p

 Lowest price paid per share:                   183.00p

 Volume weighted average price paid per share:  184.65p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 15,291,716 ordinary
shares in treasury and has 274,176,443 ordinary shares in issue (excluding
treasury shares). The total number of voting rights in the Company is
therefore 274,176,443 which may be used by shareholders in their calculations
to determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as
incorporated into UK domestic law by the European Union (Withdrawal) Act 2018)
(the Market Abuse Regulation), detailed information about the individual
purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 27 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both U.S.
FDA clearance and European marketing authorization and a third (KarXT) that
has been filed for FDA approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X, formerly known as
Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

 

Individual Transactions

 Transaction Date  Transaction Time  Volume  Price (GBp)  Platform  Transaction Reference Number
 10/10/2023        09:08:04          47      183.8        CHIX      00372960335TRLO0.1.1
 10/10/2023        09:08:04          520     183.8        CHIX      00372960336TRLO0.1.1
 10/10/2023        09:08:04          57      183.6        CHIX      00372960337TRLO0.1.1
 10/10/2023        09:08:24          409     183.4        XLON      00372960411TRLO0.1.1
 10/10/2023        09:09:31          4291    183.4        XLON      00372960626TRLO0.1.1
 10/10/2023        09:09:31          381     183.2        XLON      00372960628TRLO0.1.1
 10/10/2023        09:09:31          324     183.4        XLON      00372960627TRLO0.1.1
 10/10/2023        09:09:32          17      183.2        AQXE      00372960629TRLO0.1.1
 10/10/2023        09:09:43          21      183          AQXE      00372960672TRLO0.1.1
 10/10/2023        09:09:43          190     183.2        AQXE      00372960671TRLO0.1.1
 10/10/2023        09:11:49          45      183          XLON      00372960973TRLO0.1.1
 10/10/2023        09:11:49          200     183.2        XLON      00372960975TRLO0.1.1
 10/10/2023        09:11:49          5       183.2        XLON      00372960974TRLO0.1.1
 10/10/2023        09:12:43          52      183.2        CHIX      00372961406TRLO0.1.1
 10/10/2023        09:12:43          3       183.2        XLON      00372961407TRLO0.1.1
 10/10/2023        09:22:02          9       184.4        XLON      00372964525TRLO0.1.1
 10/10/2023        15:14:45          235     185.8        XLON      00373075547TRLO0.1.1
 10/10/2023        15:14:45          387     185.8        XLON      00373075548TRLO0.1.1
 10/10/2023        15:14:45          235     185.8        XLON      00373075549TRLO0.1.1
 10/10/2023        15:14:45          235     185.8        XLON      00373075550TRLO0.1.1
 10/10/2023        15:14:45          5429    185.8        XLON      00373075551TRLO0.1.1
 10/10/2023        15:14:45          52      185.8        CHIX      00373075552TRLO0.1.1
 10/10/2023        15:14:45          52      185.8        CHIX      00373075554TRLO0.1.1
 10/10/2023        15:14:45          52      185.8        CHIX      00373075553TRLO0.1.1
 10/10/2023        15:14:45          52      185.8        CHIX      00373075555TRLO0.1.1
 10/10/2023        15:14:45          52      185.8        CHIX      00373075556TRLO0.1.1
 10/10/2023        15:14:45          288     185.8        CHIX      00373075558TRLO0.1.1
 10/10/2023        15:14:45          52      185.8        CHIX      00373075557TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSFLFSDIILILIV